The COVID-19 pandemic has further revealed a discrepancy patients face in their out-of-pocket costs for oral chemotherapy drugs in contrast to what they pay for IV therapies.
As you may know, many cancer patients today are covered under antiquated insurance benefit designs which require patients to pay more out-of-pocket costs for anticancer treatments delivered by pill instead of IV. This discrepancy is simply based on the form of administration. Unfortunately, with COVID-19 this unnecessary discrepancy in cost-sharing means that many cancer patients face greater financial barriers to oral anticancer therapies. Simply put, this places patients and their families at risk of contracting COVID-19 and the Cancer Drug Parity Act would mitigate this risk.
Was this helpful?